Cargando…
Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma
Immune checkpoint blockade (ICB) therapy is a treatment strategy for hepatocellular carcinoma (HCC); however, its clinical efficacy is limited to a select subset of patients. Next-generation sequencing has identified the value of tumor mutation burden (TMB) as a predictor for ICB efficacy in multipl...
Autores principales: | Li, Li, Rao, Xiaosong, Wen, Zhaohong, Ding, Xiaosheng, Wang, Xiangyi, Xu, Weiran, Meng, Chao, Yi, Yuting, Guan, Yanfang, Chen, Yongshen, Wang, Jiayin, Jun, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068659/ https://www.ncbi.nlm.nih.gov/pubmed/32218826 http://dx.doi.org/10.3892/ol.2020.11372 |
Ejemplares similares
-
Next Generation Sequencing‐Based Identification of T‐Cell Receptors for Immunotherapy Against Hepatocellular Carcinoma
por: Ma, Yipeng, et al.
Publicado: (2021) -
Next-Generation Immunotherapies to Improve Anticancer Immunity
por: Shi, Yaoyao, et al.
Publicado: (2021) -
Melanoma Immunotherapy: Next-Generation Biomarkers
por: Hogan, Sabrina A., et al.
Publicado: (2018) -
Next-generation cytokines for cancer immunotherapy
por: Xue, Diyuan, et al.
Publicado: (2021) -
Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy
por: Sonabend, Adam M., et al.
Publicado: (2021)